We are live on ! Find out more
SAM

Sectoral Asset Management Portfolio holdings

AUM $121M
1-Year Est. Return 73.47%
This Fund
S&P 500
This Quarter Est. Return
+15.26%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$125M
AUM Growth
-$37.3M
Cap. Flow
-$58.8M
Cap. Flow %
-47.11%
Top 10 Hldgs %
46.07%
Holding
88
New
6
Increased
20
Reduced
44
Closed
14

Top Buys

Rank Stock Value
1
EVMN
Evommune Inc
EVMN
+$11.1M
2
LENZ
LENZ Therapeutics
LENZ
+$1.24M
3
JNJ icon
Johnson & Johnson
JNJ
+$989K
4
COGT icon
Cogent Biosciences
COGT
+$919K
5
AMGN icon
Amgen
AMGN
+$866K

Top Sells

Rank Stock Value
1
GPCR icon
Structure Therapeutics
GPCR
+$8.08M
2
VTYX
Ventyx Biosciences
VTYX
+$7.55M
3
RCUS icon
Arcus Biosciences
RCUS
+$6.35M
4
ANAB icon
AnaptysBio
ANAB
+$5.96M
5
IMTX icon
Immatics
IMTX
+$5.02M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AZN icon
26
AstraZeneca
AZN
$263B
$1.4M 1.12%
7,616
-1,759
-19% -$309K
SMMT icon
27
Summit Therapeutics
SMMT
$10.4B
$1.39M 1.12%
79,625
+5,555
+7% +$105K
RCUS icon
28
Arcus Biosciences
RCUS
$3.55B
$1.36M 1.09%
56,945
-311,125
-85% -$6.35M
SNDX icon
29
Syndax Pharmaceuticals
SNDX
$1.69B
$1.29M 1.03%
61,200
-18,230
-23% -$318K
TARS icon
30
Tarsus Pharmaceuticals
TARS
$2.58B
$1.21M 0.97%
14,740
-3,665
-20% -$274K
ALNY icon
31
Alnylam Pharmaceuticals
ALNY
$27.5B
$1.19M 0.95%
2,990
-283
-9% -$125K
RAPP
32
Rapport Therapeutics
RAPP
$1.96B
$1.18M 0.95%
38,925
-4,555
-10% -$126K
COGT icon
33
Cogent Biosciences
COGT
$6.65B
$1.16M 0.93%
+32,685
New +$919K
MLYS icon
34
Mineralys Therapeutics
MLYS
$2.25B
$1.15M 0.92%
31,625
-2,260
-7% -$90.6K
TRVI icon
35
Trevi Therapeutics
TRVI
$2.59B
$1.05M 0.85%
84,255
-21,695
-20% -$251K
ROIV icon
36
Roivant Sciences
ROIV
$24.5B
$984K 0.79%
45,347
-4,660
-9% -$91.9K
TECX
37
Tectonic Therapeutic
TECX
$529M
$881K 0.71%
42,255
-150,515
-78% -$2.8M
VTYX
38
DELISTED
Ventyx Biosciences
VTYX
$875K 0.7%
96,945
-1,010,322
-91% -$7.55M
BBIO icon
39
BridgeBio Pharma
BBIO
$15.7B
$854K 0.68%
11,170
-2,480
-18% -$163K
UTHR icon
40
United Therapeutics
UTHR
$25.8B
$840K 0.67%
1,723
+958
+125% +$446K
BOLD
41
Boundless Bio
BOLD
$56.2M
$814K 0.65%
678,574
– –
ONC
42
BeOne Medicines Ltd
ONC
$32.8B
$810K 0.65%
2,665
-4,536
-63% -$1.48M
RDNT icon
43
RadNet
RDNT
$5.02B
$785K 0.63%
11,000
+1,000
+10% +$77.2K
AVBP icon
44
ArriVent BioPharma
AVBP
$1.39B
$770K 0.62%
38,255
-980
-2% -$20.4K
QURE icon
45
uniQure
QURE
$3.03B
$732K 0.59%
30,585
-155
-0.5% -$5.98K
ASND icon
46
Ascendis Pharma A/S
ASND
$16B
$694K 0.56%
3,254
-347
-10% -$71.7K
LENZ
47
LENZ Therapeutics
LENZ
$166M
$680K 0.55%
+42,500
New +$1.24M
PFE icon
48
Pfizer
PFE
$143B
$676K 0.54%
27,150
-50,000
-65% -$1.26M
INSP icon
49
Inspire Medical Systems
INSP
$1.45B
$664K 0.53%
+7,200
New +$689K
IONS icon
50
Ionis Pharmaceuticals
IONS
$8.6B
$662K 0.53%
8,365
-840
-9% -$63.3K
1
2
3 4

Similar funds

RIP
Reliant Investment Partners Pinehurst, North Carolina $121M AUM 34.77% 1-Year Est. Return
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
CF
Conquis Financial Milbrae, California $121M AUM 16.22% 1-Year Est. Return
WIM
Wiregrass Investment Management Thomasville, Georgia $121M AUM
MW
Merited Wealth North Bay Village, Florida $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM
AAA
AG Asset Advisory Los Angeles, California $121M AUM 10.78% 1-Year Est. Return
TGM
Tenzing Global Management San Francisco, California $121M AUM 85.62% 1-Year Est. Return

Sectoral Asset Management's Q4 2025 Portfolio in Review

As of Q4 2025, Sectoral Asset Management held 88 positions worth $125M, down 23% from $162M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Sectoral Asset Management withdrew a net $58.8M in Q4 2025, closing 14 positions and reducing 44 holdings. Its most notable exit was AnaptysBio, an estimated $5.96M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier.

Against the trend, Sectoral Asset Management opened a new position in Evommune Inc worth $10.1M.

  • Sectoral Asset Management's largest Q4 2025 buy was Evommune Inc: 589,005 shares worth $10.1M.
  • Sectoral Asset Management added most to Johnson & Johnson in Q4 2025, an estimated $989K increase.
  • Sectoral Asset Management's biggest Q4 2025 reduction was Structure Therapeutics, cutting an estimated $8.08M.
  • Sectoral Asset Management fully exited AnaptysBio in Q4 2025, selling an estimated $5.96M.
  • Sectoral Asset Management's ten largest holdings make up 46% of its $125M portfolio in Q4 2025.
  • Sectoral Asset Management opened 6 new positions and closed 14 in Q4 2025.
  • Sectoral Asset Management's portfolio value fell 23% quarter-over-quarter to $125M.

Based on Sectoral Asset Management's 13F filing for Q4 2025, filed 9 Feb 2026.